Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 13.52B P/E - EPS this Y 50.00% Ern Qtrly Grth -
Income -518.25M Forward P/E -31.12 EPS next Y 57.80% 50D Avg Chg 7.00%
Sales 285.14M PEG - EPS past 5Y - 200D Avg Chg 32.00%
Dividend N/A Price/Book 18.97 EPS next 5Y - 52W High Chg -3.00%
Recommedations 1.80 Quick Ratio 6.77 Shares Outstanding 181.91M 52W Low Chg 101.00%
Insider Own 1.32% ROA -17.39% Shares Float 158.77M Beta 0.01
Inst Own 48.66% ROE -51.94% Shares Shorted/Prior 10.98M/10.51M Price 74.99
Gross Margin -84.62% Profit Margin -181.75% Avg. Volume 702,648 Target Price 86.16
Oper. Margin -152.34% Earnings Date May 13 Volume 322,630 Change 0.50%
About Legend Biotech Corporation

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Legend Biotech Corporation News
04/22/24 CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
04/11/24 Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results
04/08/24 FDA Expands J&J's (JNJ) Carvykti Label in Multiple Myeloma
04/08/24 Why Legend Biotech (LEGN) Stock Might be a Great Pick
04/05/24 Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
04/03/24 Should You Continue to Hold Legend Biotech Corporation (LEGN)?
03/29/24 Management’s Conservative Guidance Led Legend Biotech Corporation (LEGN) to Decline in Q4
03/19/24 Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report
03/17/24 30 Biggest Biotechnology Companies in the World
03/15/24 CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma
03/12/24 Legend Biotech Corporation (NASDAQ:LEGN) Q4 2023 Earnings Call Transcript
03/11/24 The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys
03/11/24 Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights
03/08/24 5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024
02/24/24 An Intrinsic Calculation For Legend Biotech Corporation (NASDAQ:LEGN) Suggests It's 47% Undervalued
02/23/24 Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy
02/13/24 Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2023 Results
02/07/24 Matthews Emerging Markets Small Companies Fund Bolsters Position in CarTrade Tech Ltd
01/22/24 UPDATE 6-US FDA seeks 'boxed warning' for CAR-T cancer therapies
01/22/24 US FDA requires 'boxed warning' for CAR-T cancer therapies
LEGN Chatroom

User Image M105 Posted - 1 day ago

$LEGN lol Wishful thinking, but no. ER is May 13th, so it’s uphill from here on.. sorry, you missed the ride up

User Image Unicorn2020 Posted - 2 days ago

$LEGN It's a great idea to set trailing stop and got out with a little profit today. This thing will go down to $40. I will come back. GS upgraded BUY with PT $90, Scotiabank $65. They are taking it low for tutes to buy in. Keep my eyes on this one.

User Image Myardiny_Toe Posted - 3 days ago

$LEGN,,,, https://www.forbes.com/sites/jakezamansky/2013/08/08/the-great-vampire-squid-keeps-on-sucking/?sh=47c5415e7df8

User Image M105 Posted - 3 days ago

$LEGN Something tells me this is opening tomorrow above $50 and will race to over $55. Now that the US & EU have approved it as 2nd line treatment, they have opened the flood gate to sheer market dominance for Legend

User Image jewell69 Posted - 3 days ago

$LEGN just bot 100 at 36.30 just 2 b prudent, canceled buy order of 201 $FDMT at 25.04

User Image jewell69 Posted - 3 days ago

$LEGN tryin 2 buy 100 at 46.30

User Image Unicorn2020 Posted - 3 days ago

$LEGN Bought 3K shares @ $47 today. Long.

User Image Stock_Titan Posted - 4 days ago

$LEGN CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma https://www.stocktitan.net/news/LEGN/carvykti-r-ciltacabtagene-autoleucel-approved-by-the-european-039ub826mv0z.html

User Image MaxDanger Posted - 4 days ago

$LEGN the stock has sold off 20% in 2 weeks. I think this was the flush it needed to move higher as we go into the ASCO meeting in a few weeks.

User Image Quantumup Posted - 1 week ago

BMO Capital $LEGN Outperform/$90: "1Q24 Sales Missed Consensus by ~8%; We Don't see any Long-Term Impact" BMO expects the 2L approval2 sig'ly expand the addressable pop/demand +w/ mfg'g scaling will enable Carvykti sales2meet/beat '24 cons expys (~$1B): $ACLX $jnj $gild $tsvt bmy

User Image Thestocktraderhubzee Posted - 1 week ago

$LEGN HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $87 Price Target

User Image Stock_Titan Posted - 2 weeks ago

$LEGN Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results https://www.stocktitan.net/news/LEGN/legend-biotech-to-host-investor-conference-call-on-first-quarter-xj52ewdvn1do.html

User Image Bidzill Posted - 2 weeks ago

$LEGN I feel like the market is sleeping on this one. Can anyone tell me what the event was the night before or morning of January 23 here? I see it gapped down at open and recovered throughout the day on elevated volume. Any insight is appreciated!

User Image Bidzill Posted - 2 weeks ago

Accidentally removed handle tag: $LEGN

User Image Bidzill Posted - 2 weeks ago

$LEGN

User Image Broncos07 Posted - 2 weeks ago

$LEGN and glad i did.

User Image Broncos07 Posted - 2 weeks ago

$LEGN just moved to bullish!!!!

User Image Broncos07 Posted - 2 weeks ago

$LEGN very nice.

User Image jewell69 Posted - 2 weeks ago

$LEGN bot 4/8 54.48 Sold now 4/9 54.98

User Image M105 Posted - 2 weeks ago

$LEGN Do not be bothered, get ready for some serious momentum here, big hitting investment banks including JP Morgan & Barclays etc raised their PT yesterday and have recommended a strong buy. A 70% to 100% upside on the table now

User Image jewell69 Posted - 2 weeks ago

$LEGN another CAR-T $XBI bot just now; 1st time trade 04/08/2024 01:57:21 PM ET $54.48 50.000 $2,724.00 Ms. Gena Wang 4/8/24 REITERATED buy pt now 94; not sure what it was b4. she is 4.5 stars Barclays Wall Street Analyst #917 out of 8,789 Wall Street Analysts #2,133 out of 37,300 experts tip ranks says strong buy 13/15 say buy; 2 say hold pt range: 100 to 65 a 'hold' analyst

User Image OpenOutcrier Posted - 2 weeks ago

$LEGN (+1.0% pre) Legend Biotech’s CARVYKTI® Revolutionizes Multiple Myeloma Treatment - tr https://ooc.bz/l/29709

User Image Broncos07 Posted - 2 weeks ago

$IVP $SBFM $GTCS $TSVT….. not advice. Do your DD. Last one $LEGN lets get this!!!!

User Image Broncos07 Posted - 2 weeks ago

$LEGN still holding mine….

User Image tradingtwenty Posted - 2 weeks ago

Top 5 trending stocks in the past 24 hours (based on 5 minute intervals): $MUSA 180 🔥 $LEGN 169 $PI 168 $PATH 144 $UBER 137 Link: https://tradingtwenty.com/dashboard/trending/past

User Image RiskVsReward Posted - 2 weeks ago

$LEGN Ill be watching you... ✔️

User Image M105 Posted - 2 weeks ago

$TSVT $LEGN These 2 stocks are not an either / or option, institutional investors do not assess things the way retail day traders do. They are a win/win scenario, that is why they are buying up both stocks. Simply put, whether after One or Two Prior Lines of Therapy, all the likes of Goldman Sachs, Barclays, Vanguard group, Madison Avenue etc are concerned with is to make profit at each stage, that is why they are pilling up both stocks. Also,iIt's precisely why you find analyst reporting on both simultaneously, cos each targets different stages .... so quit thinking one will take a pounding. Institutional investors know that they will make money investing in both... It's an upstream /downstream pespective they are taking. If CARVYKTI is administered after 1 therapy, Abecma is 100% certain to be the next therapy (i.e., post 2 therapies). Get it now? That is precisely why both stocks will fly overnight tonight and into PM, and then go ballistic at the bell.

User Image JerryMalone32 Posted - 2 weeks ago

@M105 @valueforme @Bovan @Rabinovich You wrote, "the current SP will start moving ... upwards Monday. $tsvt and $legn FDA approvals will drag one another up in value at varying degrees." You mean sort've like the Casgevy and Lyfgenia approvals in December have dragged up $Crsp and $blue ;)

User Image RiskVsReward Posted - 2 weeks ago

$LEGN Charting for you🔥

User Image bill15701 Posted - 2 weeks ago

$LEGN Very Bullish - This FDA approval positions CARVYKTI® as a groundbreaking treatment in the multiple myeloma space, likely leading to a very bullish sentiment for Legend Biotech’s stock (LEGN) in the short term.

Analyst Ratings
HC Wainwright & Co. Buy Apr 23, 24
Scotiabank Sector Outperform Apr 17, 24
HC Wainwright & Co. Buy Apr 16, 24
Cantor Fitzgerald Overweight Apr 3, 24
HC Wainwright & Co. Buy Apr 1, 24
UBS Buy Mar 18, 24
HC Wainwright & Co. Buy Mar 18, 24
HC Wainwright & Co. Buy Mar 13, 24
Raymond James Outperform Mar 13, 24